The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.

导出 OA

翻译打印收藏纠错

作者： Gi-June,Min ^[1] ; Young-Woo,Jeon ^[1] ; Sung-Soo,Park ^[1] ; Silvia,Park ^[1] ; Seung-Hawn,Shin ^[2] ; Seung-Ah,Yahng ^[3] ; Jae-Ho,Yoon ^[1] ; Sung-Eun,Lee ^[1] ; Byung-Sik,Cho ^[1] ; Ki-Seong,Eom ^[1] ; Yoo-Jin,Kim ^[1] ; Seok,Lee ^[1] ; Hee-Je,Kim ^[1] ; Chang-Ki,Min ^[1] ; Dong-Wook,Kim ^[1] ; Jong-Wook,Lee ^[1] ; Seok-Goo,Cho ^[1]

作者单位： Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. ^[1] Department of Hematology, Yeouido St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. ^[2] Department of Hematology, Incheon St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. ^[3]

关键词 Interleukin-6 Multi-centric Castleman's disease Siltuximab Tolerance

主题词抗体, 单克隆(Antibodies, Monoclonal);人类(Humans);实验室(Laboratories);回顾性研究(Retrospective Studies)

DOI 10.3904/kjim.2019.330

PMID 32088937

发布时间 2021-06-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交